Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Rotigotine: in Parkinson's disease.

Neil A Reynolds1, Keri Wellington, Stephanie E Easthope

  • 1Adis International Limited, Auckland, New Zealand. demail@adis.co.nz

CNS Drugs
|November 5, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Drospirenone/ethinylestradiol 3mg/20microg (24/4 day regimen): a review of its use in contraception, premenstrual dysphoric disorder and moderate acne vulgaris.

Drugs·2007
Same author

Spotlight on bicalutamide 150mg in the treatment of locally advanced prostate cancer.

Drugs & aging·2007
Same author

Bicalutamide 150mg: a review of its use in the treatment of locally advanced prostate cancer.

Drugs·2006
Same author

Insulin glulisine.

Drugs·2006
Same author

Modified-release nifedipine: a review of the use of modified-release formulations in the treatment of hypertension and angina pectoris.

Drugs·2006
Same author

0.4% nitroglycerin ointment : in the treatment of chronic anal fissure pain.

Drugs·2006

Rotigotine, a transdermal dopamine agonist, effectively improved symptoms in early Parkinson's disease patients. It also reduced "off" time in advanced Parkinson's patients when used with levodopa.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Clinical Medicine

Background:

  • Rotigotine is a nonergoline dopamine receptor agonist.
  • It is delivered via a transdermal system.
  • Evaluated for idiopathic Parkinson's disease treatment.

Purpose of the Study:

  • To assess the efficacy of rotigotine monotherapy in early Parkinson's disease.
  • To evaluate rotigotine as adjunctive therapy with levodopa in advanced Parkinson's disease.
  • To determine the safety and tolerability of rotigotine.

Main Methods:

  • Two large, well-designed clinical trials were conducted.
  • Patients received either rotigotine monotherapy or rotigotine plus levodopa.
  • Efficacy was measured by Unified Parkinson's Disease Rating Scale scores and reduction in 'off' time.

Related Experiment Videos

Main Results:

  • Rotigotine monotherapy significantly improved parkinsonian symptoms compared to placebo in early Parkinson's disease.
  • Significant benefits were observed with 30 and 40 cm2 rotigotine patches.
  • Rotigotine as adjunctive therapy significantly reduced 'off' time in advanced Parkinson's disease patients.

Conclusions:

  • Rotigotine is an effective treatment for early Parkinson's disease.
  • Rotigotine provides significant benefits for advanced Parkinson's disease patients.
  • Rotigotine was generally well-tolerated with mild to moderate adverse events.